Alterações funcionais hepáticas induzidas pelo uso concomitante de isoniazida, pirazinamida e rifampicina no tratamento da tuberculose pulmonar

Arquivos de Gastroenterologia

Volumn 33, Issue 4, 1996, Pages 194-200

  De Souza, Aécio Flávio Meirelles ^a,b,e   De Oliveira e Silva, Adávio ^c   Baldi, Jorge ^a   De Souza, Terezinha N Pires Alves ^a   Rizzo, Patrícia Maria Martins ^d  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b IBEPEGE   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Hosp Dr Joao Penido

^e NONE   (Brazil)

Author keywords

Hepatitis; Isoniazid; Pulmonary; Pyrazinamide; Rifampin; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGE; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; LIVER DISEASE; LUNG TUBERCULOSIS; MALE; MIDDLE AGED; SEX DIFFERENCE; CHOLESTASIS; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY;

ADULT; AGE FACTORS; AGED; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; ISONIAZID; LIVER DISEASES; MALE; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; SEX FACTORS; TUBERCULOSIS, PULMONARY;

EID: 0030423489     PISSN: 00042803     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Acocella G, Mattiusi R, Nicolis FB, Tenconi R. Billiary excretion of antibiotics in man. Gut, 9:536, 1995.
2. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid associated hepatitis in 114 patients.Gastroenterology, 69:239, 1975.
3. George CP, George RH. The liver response to drug. In: Wright R, Mellucid-Saller GH, Alberti KGMM, Koran S, ed. Liver and biliary disease. 2.ed. London, WB Saunders, 1985. p.414-52.
4. Gronhagen-Riska C, Hellstron PE, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis. Am Rev Respir Dis, 118:461, 1978.
5. Hilary AW, Lance N, Elaine M, Michael DR, Kenneth WW, Oliver FWJ. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology, 2:297, 1989.
6. Jewell SA, Dimonti D, Gentili H, Gruguelmi AXA, Altomare A, Albano A. Decrease hepatic glutation in chronic alcoholic patients. J Hepatol, 1:1, 1986.
7. Kato R. Sex-related differences in drug metabolism. Drug Metab Rev, 3:1, 1974.
8. Kato R, Takanaka A. A metabolism of drug in old rats. II. Metabolism in vitro and effect of drugs in old rats. Jpn J Pharmacol, 19:385, 1968.
9. Kato R, Vassanelli P, Frentino P. Variation in the activity of liver microssomal drug-metabolizing enzymes in rats in relation to age. Biochem Pharmacol, 20:1037, 1964.
10. Koff RS, Gardner R, Hariwasuta V, Phill CO. Profile of hyperbilirrubinemia in three hospital population. Clin Res, 18:680, 1970.
11. Leis AW, Allan GW, Smith J, Tyrrel NF, Fallon RS. Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle, 52:182, 1971.
12. Lesorbre R, Rufino J, Teyssier L, Achard F, Breforf C. Les ictères au cours du traitement par la rifampicine. Rev Tuberc Pneumol, 33:353, 1969.
13. Maddrey WC. Isoniazid-induced liver disease. Semin Liver Dis, 1:129, 1981.
14. Midleton HM, Dunn GV, Schenker S. Alcohol-induced liver injury. Pathogenic consideration. In: Becker BFF, ed. The liver. New York, Marcel Decker, 1974. p.638-47.
15. Mitchell JR, Thorgeirsson UP, Black M, Tinbell JA, Potter WZ, Snodgrass W. Increased incidence of isoniazid hepatitis in rapid acetylators. Possible relation to lydrazine metabolites. Clin Pharmacol Ther, 18:70, 1975.
16. Mitchell JR, Nelson SD, Thorgeirsson SS, McMurtry RJ, Dybing E. Metabolic activation: biochemical basis for many drug-induced liver injuries. Prog Liver Dis, 5:259, 1976.
17. Mitchell JR, Zimmerman JH, Ishack KC. Isoniazid liver injury. Clinical spectrum pathology and probable pathogenesis. Ann Intern Med, 94:181, 1976.
18. Nolam L, Malley R. Prescribing for the elderly. I. Sensitivity-of the elderly to adverse drug reactions. J Am Geriatr Soc, 36:146, 1988.
19. Pilheu JA, Salvo MC, Barcot JA, Koch OR. Tuberculosis e ictericia. Medicina (Buenos Aires), 47:13, 1967.
20. Remmer H. The role of the liver in drug metabolism. Am J Med, 49:617, 1980.
21. Scheur PJ, Summersfield JA, Lai S, Sherlock S. Rifanpicin hepatitis. Lancet, 1:421, 1974.
22. Sharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients recurring isoniazid. Ann Intern Med, 71:1113, 1969.
23. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis, 3:292, 1970.
24. Vestal RE. Aging and determinants of hepatic drug clearance. Hepatology, 7:331, 1989.
25. Yeager RL, Munroe WGC, Dessay FJ. Pyrazinamide (Aldinamide) in the treatment of pulmonary tuberculosis. Trans Nat Assoc Tuberc, 48:178, 1952.
26. Zimmerman HJ. Vulnerability of the liver to toxic injury. In: Zimmerman HJ, ed, Hepatotoxicity. New York, Appleton-Century-Crofts, 1978. p.32-46.